BR112012020101A2 - diagnostic and therapeutic methods using anti-cd200 antibodies. - Google Patents
diagnostic and therapeutic methods using anti-cd200 antibodies.Info
- Publication number
- BR112012020101A2 BR112012020101A2 BR112012020101A BR112012020101A BR112012020101A2 BR 112012020101 A2 BR112012020101 A2 BR 112012020101A2 BR 112012020101 A BR112012020101 A BR 112012020101A BR 112012020101 A BR112012020101 A BR 112012020101A BR 112012020101 A2 BR112012020101 A2 BR 112012020101A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- diagnostic
- methods
- therapeutic methods
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
métodos diagnósticos e terapêuticos usando anticorpos anti-cd200. a presente divulgação diz respeito a anticorpos anti-cd200 e ao uso dos anticorpos em métodos para o tratamento de distúrbios autoimunes e câncer. também são apresentados biomarcadores para uso na seleção ou prescrição de uma modalidade de tratamento para um paciente com um distúrbio autoimune e/ou câncer. além disso, a divulgação apresenta métodos de tratamento usando um anticorpo anti-cd200 em combinação com um ou mais agentes terapêuticos adicionais, tais como um agente terapêutico anti-cd20.diagnostic and therapeutic methods using anti-cd200 antibodies. The present disclosure relates to anti-cd200 antibodies and the use of antibodies in methods for treating autoimmune disorders and cancer. Biomarkers are also provided for use in selecting or prescribing a treatment modality for a patient with an autoimmune disorder and / or cancer. further, the disclosure discloses methods of treatment using an anti-cd200 antibody in combination with one or more additional therapeutic agents, such as an anti-cd20 therapeutic agent.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33796210P | 2010-02-11 | 2010-02-11 | |
PCT/US2011/024511 WO2011100538A1 (en) | 2010-02-11 | 2011-02-11 | Therapeutic methods using an ti-cd200 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012020101A2 true BR112012020101A2 (en) | 2018-09-25 |
Family
ID=44368146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012020101A BR112012020101A2 (en) | 2010-02-11 | 2011-02-11 | diagnostic and therapeutic methods using anti-cd200 antibodies. |
Country Status (14)
Country | Link |
---|---|
US (2) | US9085623B2 (en) |
EP (1) | EP2534178A4 (en) |
JP (1) | JP2013519682A (en) |
KR (1) | KR20130036192A (en) |
CN (1) | CN102918062A (en) |
AU (1) | AU2011215750A1 (en) |
BR (1) | BR112012020101A2 (en) |
CA (1) | CA2789623A1 (en) |
IL (1) | IL221288A0 (en) |
MX (1) | MX2012009321A (en) |
NZ (1) | NZ601580A (en) |
RU (1) | RU2012138703A (en) |
SG (1) | SG182823A1 (en) |
WO (1) | WO2011100538A1 (en) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
US8680020B2 (en) | 2008-07-15 | 2014-03-25 | Academia Sinica | Glycan arrays on PTFE-like aluminum coated glass slides and related methods |
US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
JP6012473B2 (en) * | 2010-01-11 | 2016-10-25 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | Biomarker of immunomodulatory effect in human treatment with anti-CD200 antibody |
AU2011215750A1 (en) | 2010-02-11 | 2012-08-23 | Alexion Pharmaceuticals, Inc. | Therapeutic methods using an ti-CD200 antibodies |
US10338069B2 (en) | 2010-04-12 | 2019-07-02 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
DK2663579T3 (en) | 2011-01-14 | 2017-07-31 | Univ California | THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF |
JP6150734B2 (en) | 2011-02-03 | 2017-06-21 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | Use of anti-CD200 antibodies to prolong allograft survival |
EP2723380B1 (en) | 2011-06-24 | 2019-08-21 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
CN102698266A (en) * | 2012-05-15 | 2012-10-03 | 中国医学科学院北京协和医院 | Application of CD200 for preparing systemic lupus erythematosus psychotherapeutic drugs |
CA2880701A1 (en) | 2012-08-18 | 2014-02-27 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
US9447193B2 (en) * | 2013-03-24 | 2016-09-20 | Development Center For Biotechnology | Methods for suppressing cancer by inhibition of TMCC3 |
WO2014210397A1 (en) | 2013-06-26 | 2014-12-31 | Academia Sinica | Rm2 antigens and use thereof |
US9981030B2 (en) | 2013-06-27 | 2018-05-29 | Academia Sinica | Glycan conjugates and use thereof |
US9782476B2 (en) | 2013-09-06 | 2017-10-10 | Academia Sinica | Human iNKT cell activation using glycolipids with altered glycosyl groups |
US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
WO2015109180A2 (en) | 2014-01-16 | 2015-07-23 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
JP6562942B2 (en) | 2014-03-27 | 2019-08-28 | アカデミア シニカAcademia Sinica | Reactive labeled compounds and uses thereof |
SG11201608194VA (en) | 2014-04-03 | 2016-10-28 | Igm Biosciences Inc | Modified j-chain |
CA2950440A1 (en) | 2014-05-27 | 2015-12-03 | Academia Sinica | Anti-her2 glycoantibodies and uses thereof |
TWI654202B (en) | 2014-05-27 | 2019-03-21 | 中央研究院 | Composition and method for general-purpose glycoforms for enhancing antibody efficacy |
AU2015267047A1 (en) | 2014-05-27 | 2017-01-05 | Academia Sinica | Anti-CD20 glycoantibodies and uses thereof |
US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
AU2015267044A1 (en) | 2014-05-28 | 2016-12-15 | Academia Sinica | Anti-TNF-alpha glycoantibodies and uses thereof |
CA2960712A1 (en) | 2014-09-08 | 2016-03-17 | Academia Sinica | Human inkt cell activation using glycolipids |
US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
WO2016118191A1 (en) | 2015-01-24 | 2016-07-28 | Academia Sinica | Novel glycan conjugates and methods of use thereof |
CN107614521B (en) * | 2015-01-30 | 2022-02-08 | 台湾地区“中央研究院” | Universal carbohydrate compositions and methods for enhancing antibody efficacy |
KR20220018081A (en) | 2015-03-04 | 2022-02-14 | 아이쥐엠 바이오사이언스 인코포레이티드 | Cd20 binding molecules and uses thereof |
WO2017059380A1 (en) | 2015-09-30 | 2017-04-06 | Igm Biosciences, Inc. | Binding molecules with modified j-chain |
WO2017059387A1 (en) * | 2015-09-30 | 2017-04-06 | Igm Biosciences, Inc. | Binding molecules with modified j-chain |
CN107102141A (en) * | 2016-02-23 | 2017-08-29 | 中国科学院生物物理研究所 | Molecular marked compound CD71 and Endometrial Carcinomas diagnosis, the application by stages and in prognosis |
CA3016170A1 (en) | 2016-03-08 | 2017-09-14 | Academia Sinica | Methods for modular synthesis of n-glycans and arrays thereof |
RU2756236C2 (en) | 2016-06-20 | 2021-09-28 | Кимаб Лимитед | Pd-l1 specific antibodies |
WO2018014001A1 (en) | 2016-07-14 | 2018-01-18 | Fred Hutchinson Cancer Research Center | Multiple bi-specific binding domain constructs with different epitope binding to treat cancer |
EP3500594A4 (en) * | 2016-08-22 | 2020-03-11 | Cho Pharma Inc. | Antibodies, binding fragments, and methods of use |
WO2018075408A1 (en) | 2016-10-17 | 2018-04-26 | Alexion Pharmaceuticals, Inc. | Methods of treating acute myeloid leukemia (aml) with combinations of anti-cd200 antibodies, cytarabine, and daunorubicin |
WO2018102594A1 (en) | 2016-12-01 | 2018-06-07 | Alexion Pharmaceuticals, Inc. | Methods of treating solid tumors with anti-cd200 antibodies |
US11761963B2 (en) | 2017-09-27 | 2023-09-19 | Alexion Pharmaceuticals, Inc. | Biomarker signature for predicting tumor response to anti-CD200 therapy |
US11802154B2 (en) | 2017-12-20 | 2023-10-31 | Alexion Pharmaceuticals, Inc. | Humanized anti-CD200 antibodies and uses thereof |
US20210087267A1 (en) | 2017-12-20 | 2021-03-25 | Alexion Pharmaceuticals, Inc. | Liquid formulations of anti-cd200 antibodies |
WO2019148186A1 (en) * | 2018-01-29 | 2019-08-01 | Silarus Therapeutics, Inc. | Antibodies binding erfe and methods of use |
KR20210069639A (en) | 2018-08-30 | 2021-06-11 | 에이치씨더블유 바이올로직스, 인크. | Single-chain chimeric polypeptides and uses thereof |
SG11202101779RA (en) | 2018-08-30 | 2021-03-30 | Hcw Biologics Inc | Multi-chain chimeric polypeptides and uses thereof |
AU2019328575A1 (en) | 2018-08-30 | 2021-02-25 | HCW Biologics, Inc. | Single-chain and multi-chain chimeric polypeptides and uses thereof |
TWI749367B (en) * | 2018-09-14 | 2021-12-11 | 美商美國禮來大藥廠 | Cd200r agonist antibodies and uses thereof |
KR20200112102A (en) | 2019-03-20 | 2020-10-05 | 주식회사 썬닷컴 | Method for cuitivating peanut sprout and system for the same |
JP2022537054A (en) | 2019-06-21 | 2022-08-23 | エイチシーダブリュー バイオロジックス インコーポレイテッド | Multichain chimeric polypeptides and uses thereof |
EP4103601A2 (en) | 2020-02-11 | 2022-12-21 | HCW Biologics, Inc. | Methods of treating age-related and inflammatory diseases |
CN115362169A (en) | 2020-02-11 | 2022-11-18 | Hcw生物科技公司 | Chromatography resins and uses thereof |
EP4103599A1 (en) | 2020-02-11 | 2022-12-21 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
AU2021262794A1 (en) | 2020-04-29 | 2022-11-24 | HCW Biologics, Inc. | Anti-CD26 proteins and uses thereof |
WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
JP2023527869A (en) | 2020-06-01 | 2023-06-30 | エイチシーダブリュー バイオロジックス インコーポレイテッド | Treatments for age-related disorders |
CN115873902A (en) * | 2021-11-30 | 2023-03-31 | 百奥赛图(北京)医药科技股份有限公司 | Non-human animal humanized by CD200 and/or CD200R gene and construction method and application thereof |
WO2023168363A1 (en) | 2022-03-02 | 2023-09-07 | HCW Biologics, Inc. | Method of treating pancreatic cancer |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0170697B1 (en) | 1984-02-08 | 1991-10-23 | Cetus Oncology Corporation | Toxin conjugates |
JPH0246297A (en) | 1988-08-08 | 1990-02-15 | Takeda Chem Ind Ltd | Production of monoclonal antibody, antibody-producing hybridoma and antibody |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
ATE196606T1 (en) | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | THERAPEUTIC USE OF CHIMERIC AND LABELED ANTIBODIES DIRECTED AGAINST A DIFFERENTIATION ANTIGEN WHICH EXPRESSION IS RESTRICTED TO HUMAN B LYMPHOCYTES, FOR THE TREATMENT OF B-CELL LYMPHOMA |
US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
WO1997021450A1 (en) | 1995-12-08 | 1997-06-19 | Brigham And Women's Hospital, Inc. | Ox-2 costimulatory molecule |
US7223729B2 (en) * | 1997-11-07 | 2007-05-29 | Trillium Therapeutics Inc. | Methods of treating allergy by administering a CD200 protein |
US6955811B2 (en) * | 1997-11-07 | 2005-10-18 | Trillium Therapeutics Inc. | Methods of inhibiting immune response suppression by administering antibodies to OX-2 |
DK1032662T3 (en) | 1997-11-07 | 2006-07-03 | Trillium Therapeutics Inc | Methods and Compositions for Immunomodulation |
US20020192215A1 (en) | 1999-04-13 | 2002-12-19 | Schering Corporation, A New Jersey Corporation | Novel uses of mammalian OX2 protein and related reagents |
CA2403393A1 (en) | 2000-03-17 | 2001-09-20 | Reginald M. Gorczynski | Methods and compositions for immunoregulation |
US7306801B2 (en) | 2000-05-15 | 2007-12-11 | Health Research, Inc. | Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein |
CA2417874C (en) | 2000-08-03 | 2012-10-02 | Transplantation Technologies Inc. | Use of ox-2 inhibitors for the treatment of cancer |
AU2333802A (en) | 2000-11-22 | 2002-06-03 | Transplantation Technologies I | Truncated cd200 |
US9249229B2 (en) * | 2000-12-08 | 2016-02-02 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
US20040198661A1 (en) | 2000-12-08 | 2004-10-07 | Bowdish Katherine S. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
WO2002059280A2 (en) | 2000-12-08 | 2002-08-01 | Alexion Pharmaceuticals, Inc. | Chronic lymphocytic leukemia cell line and its use for producing an antibody |
US7408041B2 (en) * | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
US20060057651A1 (en) | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
US7368535B2 (en) | 2001-05-24 | 2008-05-06 | Trillium Therapeutics Inc. | CD200 receptors |
CA2476166C (en) | 2002-02-14 | 2011-11-15 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
US20040213783A1 (en) | 2002-12-27 | 2004-10-28 | Janet Liversidge | Methods of inducing and maintaining immune tolerance |
US20050169870A1 (en) | 2004-02-02 | 2005-08-04 | Schering Corporation | Methods of modulating CD200 |
CN101627054A (en) | 2005-07-11 | 2010-01-13 | 马克罗基因公司 | Method with the anti-CD16A Antybody therapy of humanization autoimmune disease |
US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US8075884B2 (en) * | 2006-01-12 | 2011-12-13 | Alexion Pharmaceuticals, Inc. | Antibodies to OX-2/CD200 and uses thereof |
CN101379090A (en) * | 2006-01-12 | 2009-03-04 | 阿莱克申药物公司 | Antibodies to OX-2/CD200 and uses thereof |
AU2008206502A1 (en) | 2007-01-11 | 2008-07-24 | Boehringer Ingelheim International Gmbh | CD200 and its receptor, CD200R, modulate bone mass via the differentiation of osteoclasts |
US20100267934A1 (en) * | 2007-05-31 | 2010-10-21 | Genmab A/S | Stable igg4 antibodies |
US8252285B2 (en) | 2007-07-25 | 2012-08-28 | Alexion Pharmaceuticals, Inc. | Antibodies to OX-2/CD200 and uses thereof in inhibiting immune responses |
BRPI0814645A2 (en) | 2007-07-25 | 2015-01-27 | Alexion Pharma Inc | METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASE. |
JP6012473B2 (en) | 2010-01-11 | 2016-10-25 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | Biomarker of immunomodulatory effect in human treatment with anti-CD200 antibody |
AU2011215750A1 (en) | 2010-02-11 | 2012-08-23 | Alexion Pharmaceuticals, Inc. | Therapeutic methods using an ti-CD200 antibodies |
JP6150734B2 (en) | 2011-02-03 | 2017-06-21 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | Use of anti-CD200 antibodies to prolong allograft survival |
-
2011
- 2011-02-11 AU AU2011215750A patent/AU2011215750A1/en not_active Abandoned
- 2011-02-11 NZ NZ601580A patent/NZ601580A/en not_active IP Right Cessation
- 2011-02-11 MX MX2012009321A patent/MX2012009321A/en not_active Application Discontinuation
- 2011-02-11 KR KR1020127023557A patent/KR20130036192A/en not_active Application Discontinuation
- 2011-02-11 JP JP2012553027A patent/JP2013519682A/en active Pending
- 2011-02-11 SG SG2012056784A patent/SG182823A1/en unknown
- 2011-02-11 CA CA2789623A patent/CA2789623A1/en not_active Abandoned
- 2011-02-11 BR BR112012020101A patent/BR112012020101A2/en not_active IP Right Cessation
- 2011-02-11 EP EP11742858.1A patent/EP2534178A4/en not_active Withdrawn
- 2011-02-11 US US13/578,367 patent/US9085623B2/en active Active
- 2011-02-11 CN CN2011800183882A patent/CN102918062A/en active Pending
- 2011-02-11 WO PCT/US2011/024511 patent/WO2011100538A1/en active Application Filing
- 2011-02-11 RU RU2012138703/10A patent/RU2012138703A/en not_active Application Discontinuation
-
2012
- 2012-08-02 IL IL221288A patent/IL221288A0/en unknown
-
2015
- 2015-06-15 US US14/739,862 patent/US9862767B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US9085623B2 (en) | 2015-07-21 |
US20160009803A1 (en) | 2016-01-14 |
MX2012009321A (en) | 2012-11-21 |
RU2012138703A (en) | 2014-03-20 |
AU2011215750A1 (en) | 2012-08-23 |
CA2789623A1 (en) | 2011-08-18 |
EP2534178A1 (en) | 2012-12-19 |
JP2013519682A (en) | 2013-05-30 |
NZ601580A (en) | 2014-11-28 |
US9862767B2 (en) | 2018-01-09 |
US20130189258A1 (en) | 2013-07-25 |
WO2011100538A1 (en) | 2011-08-18 |
SG182823A1 (en) | 2012-09-27 |
IL221288A0 (en) | 2012-10-31 |
CN102918062A (en) | 2013-02-06 |
EP2534178A4 (en) | 2013-08-07 |
KR20130036192A (en) | 2013-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012020101A2 (en) | diagnostic and therapeutic methods using anti-cd200 antibodies. | |
BR112012012610A2 (en) | combination therapy for cancer treatment and diagnostic assays for use in it | |
PH12016501728A1 (en) | Anti-angiogenesis therapy for the treatment of ovarian cancer | |
CO2017000571A2 (en) | Endogenous immunoglobulin inactivation procedure that facilitates medical procedures that are affected by the presence of endogenous immunoglobulin | |
PH12015501744A1 (en) | Therapeutic and diagnostic target for cancer comprising dll3 binding reagents | |
MY201478A (en) | Antibodies and assays for detection of folate receptor 1 | |
BR112016005816A2 (en) | COMBINATION OF ANTI-LAG-3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES TO TREAT TUMORS | |
UA118453C2 (en) | Modulation of tumor immunity | |
BR112016002000A2 (en) | CANCER DIAGNOSIS AND THERAPY INVOLVING TUMOR STEM CELLS | |
MX2016005159A (en) | Methods of diagnosing and treating eosinophilic disorders. | |
BR112015022472A2 (en) | method and system for predicting response to treatments for mental disorders | |
BR112014023005A2 (en) | quick diagnosis and personalized acne treatments | |
WO2014143807A3 (en) | Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders | |
WO2015009726A3 (en) | Medical uses of cd38 agonists | |
MX362514B (en) | Diagnostic assays and kits for detection of folate receptor 1. | |
MY167920A (en) | HUMAN ANTIBODIES TO GFRα3 AND METHODS OF USE THEREOF | |
SG195191A1 (en) | Methods and compositions of predicting activity of retinoid x receptor modulator | |
BR112016018205A8 (en) | methods of treating alzheimer's disease, patient selection, patient identification, prediction, therapeutic efficacy optimization, kit, agent use and in vitro agent use | |
PH12014502399A1 (en) | Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy | |
EA201590654A1 (en) | COMBINATION OF RASAGILIN AND PRIDOPIDINE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS, IN PARTICULAR OF HANTINGTON'S DISEASE | |
CL2015003343A1 (en) | Pharmaceutical composition comprising a modified therapeutic agent based on hemoglobin, for the treatment to treat cancer, and diagnostic images. | |
IN2012DN06309A (en) | ||
BR112015010039A2 (en) | treatment of cancer with pomalidomide in an individual with renal dysfunction | |
BR112015031950A2 (en) | Methods for Ovarian Cancer Treatment | |
BR112014018374A8 (en) | METHOD FOR PREDICTING THE RESPONSE OF A PATIENT WITH CANCER, KIT, ANTIBODY, METHOD FOR THE TREATMENT OF CANCER AND PHARMACEUTICAL COMPOSITION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30/10/2018. |